The proteinase K market size is calculated at USD 5.23 billion in 2025 and is expected to reach around USD 10.93 billion by 2034, growing at a CAGR of 8.54% for the forecasted period.Ottawa, Oct. 07, ...

RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric ...